Acute tumor lysis in T-cell leukemia induced by amsacrine.
The acridine orange derivative amsacrine (National Services Center No. 249992) was used to treat a patient with T-cell acute lymphoblastic leukemia (ALL). A 17-year-old boy had a tumor lysis syndrome after a single 200 mg/sq m dose of amsacrine. This was followed by a prolonged period of marrow hypoplasia leading to death from infection. Review of the literature and our own experience would suggest that T-cell ALL may be exquisitely sensitive to amsacrine.
D000293:Adolescent; D000609:Aminoacridines / Q000009:adverse effects*; D000677:Amsacrine; D001853:Bone Marrow / Q000473:pathology; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D010710:Phosphates / Q000097:blood*; D013601:T-Lymphocytes; D014527:Uric Acid / Q000097:blood*
D000609:Aminoacridines; D010710:Phosphates; D000677:Amsacrine; D014527:Uric Acid